Clinical Trials Logo

Neurocognitive Disorders clinical trials

View clinical trials related to Neurocognitive Disorders.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06382389 Not yet recruiting - Depression Clinical Trials

Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial-

PROTO-EHPAD
Start date: June 2024
Phase: Phase 2
Study type: Interventional

Depression in neurocognitive disorders (Alzheimers' disease and related disoders) is a highly prevalent condition, especially in nursing homes. While it is associated with significant distress, the current conventional antidepressants have shown only modest efficacy and exposed to potentially severe side effects. Recent evidence suggests that nitrous oxide (N2O) in its most commonly used packaging of EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide) has rapid antidepressant properties and a good safety profile. However, no study has investigating the antidepressant effect of EMONO in a population of depressed older adults with moderate to severe neurocognitive disorders in nursing homes. The principal goal of the PROTO-EHPAD study is to compare the changes in depressive symptoms in such individuals in a randomized controlled trial with a follow up period of 8 weeks, with a dosage escalation procedure.

NCT ID: NCT06375265 Not yet recruiting - Insomnia Clinical Trials

Digital Sleep Optimization for Brain Health Outcomes in Older Surgical Patients

SLEEP-BOOST
Start date: October 31, 2024
Phase: N/A
Study type: Interventional

The Sleep Optimization for Brain Health Outcomes in Older Surgical Patients (SLEEP-BOOST) is a pilot randomized, controlled, singled-blinded (participant) trial in major orthopedic joint surgery patients that will build on a previously clinically tested cognitive behavioral therapy for insomnia (CBT-I) mobile application paired with a wearable device (wrist actigraphy).

NCT ID: NCT06334289 Not yet recruiting - Frail Elderly Clinical Trials

A Predictive Study of Peripheral Blood Biomarkers on Postoperative Neurocognitive Dysfunction in Elderly Frail and Non-frail Patients Undergoing Gastrointestinal Surgery

Start date: April 1, 2024
Phase:
Study type: Observational

Perioperative neurocognitive impairment (PND) mainly includes acute postoperative delirium (POD) and persistent postoperative cognitive impairment (POCD), which are common postoperative complications in elderly patients. Perioperative neurocognitive impairment (PND) is attracting increasing attention, but its exact mechanism is still unclear. The diagnosis of PND lacks the gold standard, so it is difficult to determine the incidence rate. At present, the diagnosis is mainly conducted through the scale. Therefore, this study aims to explore the correlation between peripheral blood biomarkers and PND in elderly frail patients undergoing gastrointestinal surgery.

NCT ID: NCT06244875 Not yet recruiting - Clinical trials for Neurocognitive Disorders

Biological Collection of Neurocognitive Disorders

BioCogBank
Start date: February 1, 2024
Phase:
Study type: Observational

The development of biological biomarkers reflecting neuropathology has enhanced the diagnostic precision of Alzheimer's disease over the past decade, compared to the clinical diagnosis that suffers from low specificity. Patients undergoing evaluation in specialized memory clinics suspected of major or minor neurocognitive disorder are notably examined through a lumbar puncture to measure beta-amyloid 42, beta-amyloid 40, total tau, and phosphorylated tau in the cerebrospinal fluid (CSF). The purpose of this clinico-biological collection is to better characterize the existing biomarkers used in clinical practice, as well as the development of new diagnostic or prognostic biomarkers for neurodegenerative diseases causing neurocognitive disorder (Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration, in particular). The primary objective is to gain a better understanding of conventional biomarkers and to develop new diagnostic and prognostic biomarkers for neurocognitive diseases: establishing a prospective clinico-biological collection of patients evaluated in clinical practice for a neurocognitive disorder.

NCT ID: NCT06028568 Not yet recruiting - Clinical trials for Perioperative Neurocognitive Disorders

The Reliability and Validity of Perioperative Cognitive Test Network Platform for Monitoring Neurocognitive Changes

Start date: October 1, 2023
Phase:
Study type: Observational

This study aimed to analyze the reliability and validity of the results of the new designed perioperative cognitive test network platform, and to judge the reliability and scientific nature of the perioperative cognitive test. And then to explore whether the perioperative cognitive test network platform can be used to evaluate the changes of perioperative cognitive function of patients.

NCT ID: NCT05872529 Not yet recruiting - Delirium Clinical Trials

Turkish Precision Anaesthesia Study Project

TuPASProject
Start date: July 2023
Phase: N/A
Study type: Interventional

Postoperative delirium (POD) and postoperative neurocognitive disorder (PND) increase the length of hospital stay, morbidity and mortality, especially in elderly patients. Although several risk factors were determined and incidence trials were performed on the development of POD and PND, there has not yet been a multicentre, large-participant study in Turkish population. The SBI approach monitor, detect and help physicians and all perioperative team members to decrease and avoid the adverse side effects of surgery and anaesthesia. In this "before and after" design trial the incidence of POD and PND will be compared before and after education which consists processed EEG and SBI approach. The primary aim of the study is to determine the effect of education which consists processed EEG monitoring and regularly assessment of patient's stress, anxiety, pain, nausea, vomiting, thirst, hunger and better communication at the pre- and postoperative period on the incidence of POD. The secondary aim of the study is to assess the effect of the Safe Brain Initiative approach on patients' thirst feeling, stress-anxiety levels, postoperative pain, postoperative nausea and vomiting, well-being, satisfaction, length of PACU or recovery room stay, length of hospital stay, incidence of PND and in hospital and 3-month mortality. Also, the physicians', nurses' and patients satisfaction will be assessed.

NCT ID: NCT05866822 Not yet recruiting - Clinical trials for Neurocognitive Disorders

Adapted Physical Activity Education in Patients With Neurocognitive Disorder

EduAPA
Start date: May 20, 2023
Phase: N/A
Study type: Interventional

This study aims to compare the effect of a program of Adapted Physical Activity (APA) versus the same program combined with a physical activity education program (PAE). Patients suffering from neurocognitive disorders (mild or early major) will be randomized into one of the two conditions. 3 complete evaluations will be done (inclusion M0, after 3 month of intervention M3, 3 months after the end of the intervention M6). The team except that APA+PEA will be more effectiv than the APA solely, on the following criteria : level of physical activity, cogntive function and quality of life.

NCT ID: NCT05586672 Not yet recruiting - Clinical trials for Autism Spectrum Disorder

HR-EEG Contribution in Prognostic Evaluation of Language Development in Children With ASD

EE-TSA-LANG
Start date: January 2, 2023
Phase:
Study type: Observational

The goal of this prospective observational multicentric cohort study is to evaluate the clinical prognostic value of the speech tracking score of language development in children with ASD aged from 3 years to 4 years and half at inclusion. Participants will followed during 4 years with an annual visit. During these visits, each participant will be clinically evaluated (scales and tests) and performed an EEG-HR recording. Two groups will be formed, one with children diagnosed with ASD with language delay, and a control group composed of non-ASD children without language delay, matched on age and gender with the ASD group.

NCT ID: NCT05457725 Not yet recruiting - Aging Clinical Trials

Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging

Start date: May 2024
Phase: N/A
Study type: Interventional

Much of human interaction is based on trust. Aging has been associated with deficits in trust-related decision making, likely further exacerbated in age-associated neurodegenerative disease (Alzheimer's disease/AD), possibly underlying the dramatically growing public health problem of elder fraud. Optimal trust-related decision making and avoiding exploitation require the ability to learn about the trustworthiness of social partners across multiple interactions, but the role that learning plays in determining age deficits in trust decisions is currently unknown. The proposed work is conceptually embedded in the Changes in Integration for Social Decisions in Aging (CISDA) framework. This framework describes how the integration of decision-relevant information is impacted by trajectories of change in theory of mind, memory systems, and social-emotional processing with age. Two innovative trust-learning paradigms - the Social Iowa Gambling Task (sIGT) and the FLorida-Arizona Gambling Task (FLAG) - will be leveraged to test CISDA predictions. Aim: Probe the malleability of the underlying neurocircuitry of trust-learning deficits in aging. This study will utilize real-time fMRI neurofeedback to train healthy older adults in anterior cingulate cortex up-regulation toward enhanced trust-related learning in aging and confirm critical mechanisms of experience-dependent social decisions in aging. Grant R01AG072658 Aim 3: Test the malleability of trust-learning neurocircuitry toward optimized trust-related decision making in aging.

NCT ID: NCT05245903 Not yet recruiting - Alzheimer Disease Clinical Trials

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

Emerald-NRAD
Start date: May 2022
Phase:
Study type: Observational

This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.